Immix Biopharma Investor Presentation Deck

IMX-110: Direct Path To 1st Line Therapy in STS - Clinical Trial Plan ¡MX-110 Monotherapy ¡MX-110 + tislelizumab (anti-PD-1) combination Phase 1b iMX-110 Ongoing Phase 2a iMX-110 30 patients End of Phase 2a Phase 1b iMX-110 + tislelizumab (anti-PD-1) 30 patients BeiGene Trial Relapsed/refractory advanced solid tumors 1st Line Therapy Advanced STS Relapsed/refractory advanced solid tumors ¡MX-110 Establish MTD / RP2D iMX-110 at RP2D iMX-110 + tislelizumab Establish MTD / RP2D & NOVARTIS ●●● S IMMİX BIOPHARMA Status Ongoing Ongoing 55

View entire presentation